Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Completed

• Conditions: Crohn's Disease

• Registration Number: NCT01298648
• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary

This study will be conducted to assess adverse drug reactions, incidence of adverse events, and factors that may affect the safety and effectiveness of Humira for the treatment of Crohn's disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2011-01-26
• Study First Submitted QC: 2011-02-16
• Study First Posted: 2011-02-18
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Results First Submitted: 2014-01-31
• Results First Submitted QC: 2014-01-31
• Status Verified: 2014-03
• Results First Posted: 2014-03-18
• Last Update Submitted: 2018-06-01
• Last Update Posted: 2018-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1716

Inclusion Criteria

• All patients with moderate or severe active Crohn's disease who are not responding well to conventional therapy and receive Humira will be enrolled in the survey

Exclusion Criteria

Contraindications according to the Package Insert

• Patients who have serious infections
• Patients who have tuberculosis
• Patients with a history of hypersensitivity to any ingredient of Humira
• Patients who have demyelinating disease or with a history of demyelinating disease
• Patients who have congestive cardiac failure

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Crohn's Disease Activity Index (CDAI) at Baseline and Week 8	Baseline, Week 8	The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items and ranges from 0 to about 600. The 8 items are frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Low scores indicate low activity of Crohn's disease. In general, CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease.
Crohn's Disease Activity Index (CDAI) at Baseline and Week 24	Baseline, Week 24	The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items and ranges from 0 to about 600. The 8 items are frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Low scores indicate low activity of Crohn's disease. In general, CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease.
Crohn's Disease Activity Index (CDAI) at Baseline and Week 4	Baseline, Week 4	The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items and ranges from 0 to about 600. The 8 items are frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Low scores indicate low activity of Crohn's disease. In general, CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease.
Number of Participants With Adverse Events (AEs)	24 weeks	An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. An Adverse Drug Reaction (ADR) is any noxious and undesired reaction related to an experimental drug or experiment. A serious AE (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. AEs were rated for severity as either Mild: transient and easily tolerated; Moderate: causes discomfort and interrupts usual activities; or Severe: causes considerable interference with usual activities, may be incapacitating or life-threatening. AEs related to adalimumab were assessed as being either probably or possibly related by the investigator. An Unexpected ADR is an ADR for which the nature or gravity is not consistent with the applicable product information.

Secondary Outcome Measures

Name	Time	Method
Improvement Rating by Investigator at Week 24	Week 24	Overall response rating, according to investigator's subjective clinical opinion. The level of improvement (markedly improved, improved, not improved, or not assessable) was categorized by comparing clinical condition at week 24 or at discontinuation with baseline condition.
Remission Rate at Week 4, Week 8, and Week 24	Baseline, Week 4, Week 8, and Week 24	The remission rate for each evaluation timepoint (Weeks 4, 8, and 24) was calculated as the number of participants that had CDAI \< 150 divided by the number of participants at Baseline that had CDAI scores ≥ 150.

Trial Locations

Locations (1131)

Site Reference ID/Investigator# 60378; 🇯🇵 Abiko, Japan

Site Reference ID/Investigator# 48682; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 48693; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 49011; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 49013; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 49015; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 49016; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 49019; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 55615; 🇯🇵 Aichi, Japan

Site Reference ID/Investigator# 55616; 🇯🇵 Aichi, Japan

Scroll for more (1121 remaining)